Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie L Woolley

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Drug Targets. CNS and Neurological Disorders|February 18, 2004
5-ht6 receptorsMarie L Woolley, Charles A Marsden, Kevin C F Fone
Psychopharmacology|July 25, 2009
Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the ratSamantha L McLean, Marie L Woolley, Dave Thomas, et al.
Behavioural Brain Research|February 20, 2008
A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female ratsSamantha L McLean, Jonathan P Beck, Marie L Woolley, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 10, 2009
D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophreniaSamantha L McLean, Nagi F Idris, Marie L Woolley, et al.
Psychopharmacology|September 19, 2003
Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790Marie L Woolley, Charles A Marsden, Andrew J Sleight, et al.
Psychopharmacology|March 2, 2005
The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparisonTheresa M Ballard, Marie L Woolley, Eric Prinssen, et al.
European Journal of Pharmacology|December 30, 2008
Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout miceMarie L Woolley, Helen J Carter, Jane E Gartlon, et al.
Behavioural Pharmacology|November 21, 2008
Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in ratMarie L Woolley, Kerry A Waters, Charlie Reavill, et al.
British Journal of Pharmacology|December 24, 2016
Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulatorSimon E Ward, Paul Beswick, Novella Calcinaghi, et al.
Psychopharmacology|September 3, 2008
Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040Eric Southam, Jackie Cilia, Jane E Gartlon, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Drug Targets. CNS and Neurological Disorders|February 18, 2004
5-ht6 receptorsMarie L Woolley, Charles A Marsden, Kevin C F Fone
Psychopharmacology|July 25, 2009
Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the ratSamantha L McLean, Marie L Woolley, Dave Thomas, et al.
Behavioural Brain Research|February 20, 2008
A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female ratsSamantha L McLean, Jonathan P Beck, Marie L Woolley, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 10, 2009
D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophreniaSamantha L McLean, Nagi F Idris, Marie L Woolley, et al.
Psychopharmacology|September 19, 2003
Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790Marie L Woolley, Charles A Marsden, Andrew J Sleight, et al.
Psychopharmacology|March 2, 2005
The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparisonTheresa M Ballard, Marie L Woolley, Eric Prinssen, et al.
European Journal of Pharmacology|December 30, 2008
Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout miceMarie L Woolley, Helen J Carter, Jane E Gartlon, et al.
Behavioural Pharmacology|November 21, 2008
Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in ratMarie L Woolley, Kerry A Waters, Charlie Reavill, et al.
British Journal of Pharmacology|December 24, 2016
Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulatorSimon E Ward, Paul Beswick, Novella Calcinaghi, et al.
Psychopharmacology|September 3, 2008
Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040Eric Southam, Jackie Cilia, Jane E Gartlon, et al.
Pageof 2